Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough

Stock Track

04-17

Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.

BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.

Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1181488210"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181488210\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1181488210?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181488210","market":"us","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.</p>\n\n<p>BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.</p>\n\n<p>Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-17 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.</p>\n\n<p>BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.</p>\n\n<p>Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1181488210","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181488210","pubTimestamp":1744895823,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S  shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"由于分析师下调评级和竞争对手的突破，诺和诺德股价盘前暴跌7.57%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.\nBMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.\nAdding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}